1 - 25 of 28 results for author:"Kulozik A.E." in Literature citations
Results Customize
› Repeat search in UniProtKB (10)
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., Pfaff E., Tonjes M., Sill M., Bender S. et al. Cancer Cell 22:425-437(2012) · Mapped (12) |
| Nestin expression identifies ependymoma patients with poor outcome. Milde T., Hielscher T., Witt H., Kool M., Mack S.C., Deubzer H.E., Oehme I., Lodrini M., Benner A., Taylor M.D. et al. Brain Pathol. 22:848-860(2012) · Mapped (6) |
| A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL. Haemmerling S., Behnisch W., Doerks T., Korbel J.O., Bork P., Moog U., Hentze S., Grasshoff U., Bonin M., Riess O. et al. Br. J. Haematol. 157:180-187(2012) · Mapped (12) |
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tonjes M. et al. Nature 482:226-231(2012) · Mapped (3) |
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Rausch T., Jones D.T., Zapatka M., Stutz A.M., Zichner T., Weischenfeldt J., Jager N., Remke M., Shih D., Northcott P.A. et al. Cell 148:59-71(2012) · Mapped (33) |
| FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. Remke M., Hielscher T., Korshunov A., Northcott P.A., Bender S., Kool M., Westermann F., Benner A., Cin H., Ryzhova M. et al. J. Clin. Oncol. 29:3852-3861(2011) · Mapped (4) |
| Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. Shochat C., Tal N., Bandapalli O.R., Palmi C., Ganmore I., te Kronnie G., Cario G., Cazzaniga G., Kulozik A.E., Stanulla M. et al. J. Exp. Med. 208:901-908(2011) · Mapped (2) |
| Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Cin H., Meyer C., Herr R., Janzarik W.G., Lambert S., Jones D.T., Jacob K., Benner A., Witt H., Remke M. et al. Acta Neuropathol. 121:763-774(2011) · Mapped (3) |
| Mechanism of escape from nonsense-mediated mRNA decay of human beta-globin transcripts with nonsense mutations in the first exon. Neu-Yilik G., Amthor B., Gehring N.H., Bahri S., Paidassi H., Hentze M.W., Kulozik A.E. RNA 17:843-854(2011) · Mapped (38) |
| p38 MAPK controls prothrombin expression by regulated RNA 3' end processing. Danckwardt S., Gantzert A.S., Macher-Goeppinger S., Probst H.C., Gentzel M., Wilm M., Grone H.J., Schirmacher P., Hentze M.W., Kulozik A.E. Mol. Cell 41:298-310(2011) · Mapped (14) |
| TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. Pfaff E., Remke M., Sturm D., Benner A., Witt H., Milde T., von Bueren A.O., Wittmann A., Schottler A., Jorch N. et al. J. Clin. Oncol. 28:5188-5196(2010) · Mapped (33) |
| The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Kox C., Zimmermann M., Stanulla M., Leible S., Schrappe M., Ludwig W.D., Koehler R., Tolle G., Bandapalli O.R., Breit S. et al. Leukemia 24:2005-2013(2010) · Mapped (3) |
| Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Traenka C., Remke M., Korshunov A., Bender S., Hielscher T., Northcott P.A., Witt H., Ryzhova M., Felsberg J., Benner A. et al. Cancer Res. 70:8003-8014(2010) · Mapped (5) |
| Disassembly of exon junction complexes by PYM. Gehring N.H., Lamprinaki S., Kulozik A.E., Hentze M.W. |
| High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Remke M., Pfister S., Kox C., Toedt G., Becker N., Benner A., Werft W., Breit S., Liu S., Engel F. et al. Blood 114:1053-1062(2009) · Mapped (2) |
| Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Liu S., Breit S., Danckwardt S., Muckenthaler M.U., Kulozik A.E. Ann. Hematol. 88:613-621(2009) · Mapped (14) |
| Unexpected roles for UPF1 in HIV-1 RNA metabolism and translation. Ajamian L., Abrahamyan L., Milev M., Ivanov P.V., Kulozik A.E., Gehring N.H., Mouland A.J. RNA 14:914-927(2008) · Mapped (4) |
| Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. Ivanov P.V., Gehring N.H., Kunz J.B., Hentze M.W., Kulozik A.E. EMBO J. 27:736-747(2008) · Mapped (6) |
| The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the nonsense mediated decay pathway. Viegas M.H., Gehring N.H., Breit S., Hentze M.W., Kulozik A.E. Nucleic Acids Res. 35:4542-4551(2007) · UniProtKB (1) |
| Splicing factors stimulate polyadenylation via USEs at non-canonical 3' end formation signals. Danckwardt S., Kaufmann I., Gentzel M., Foerstner K.U., Gantzert A.S., Gehring N.H., Neu-Yilik G., Bork P., Keller W., Wilm M. et al. EMBO J. 26:2658-2669(2007) · Mapped (8) |
| Functions of hUpf3a and hUpf3b in nonsense-mediated mRNA decay and translation. Kunz J.B., Neu-Yilik G., Hentze M.W., Kulozik A.E., Gehring N.H. |
| Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. Gehring N.H., Kunz J.B., Neu-Yilik G., Breit S., Viegas M.H., Hentze M.W., Kulozik A.E. Mol. Cell 20:65-75(2005) · UniProtKB (6) |
| The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Danckwardt S., Gehring N.H., Neu-Yilik G., Hundsdoerfer P., Pforsich M., Frede U., Hentze M.W., Kulozik A.E. Blood 104:428-435(2004) · Mapped (8) |
| Homozygous and double heterozygous Factor V Leiden and Factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss. Hundsdoerfer P., Vetter B., Stover B., Bassir C., Scholz T., Grimmer I., Monch E., Ziemer S., Rossi R., Kulozik A.E. Thromb. Haemost. 90:628-635(2003) · Mapped (21) |
| Y14 and hUpf3b form an NMD-activating complex. Gehring N.H., Neu-Yilik G., Schell T., Hentze M.W., Kulozik A.E. |